The Glaucoma Market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie's Rhopressa, Bausch & Lomb's Vesneo (latanoprost bunod), and Inotek's trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market. Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market.